Cantargia: Another Investigator-Sponsored Trial Initiated - Redeye
Today, Cantargia announced the recruitment of the first patient in a new study of nadunolimab in colorectal cancer. The indication is interesting and has significant economic potential.
ANNONS
Today, Cantargia announced the recruitment of the first patient in a new study of nadunolimab in colorectal cancer. The indication is interesting and has significant economic potential.
